Cara's stock tanks as atopic dermatitis phase 2 misses endpoint

A phase 2 trial of Cara Therapeutics’ anti-itch treatment has missed its primary endpoint, sending the biotech’s stock price down 45%. Yet, Cara is forging ahead in atopic dermatitis on the strength of an efficacy signal in patients with mild-moderate disease.